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Supplementary Figure 1. Transcriptomic analysis guides the selection of panel markers. 
a. Pathways that are differentially altered from day 0 to day 3 after BRAFi treatment. Each row 
represents a certain signaling pathway and each bar indicates normalized enrichment score (NES) 
calculated from geneset enrichment analysis (GSEA) of cells harvested at day 3 versus day 0. Each 
pathway is color-coded by its functional category as described in Fig. S1b. b. Panel of markers per 
pathway selected to quantify with single-cell barcode chip (SCBC) analysis. 20 markers were 
selected for SCBC analysis. Markers with similar biological function are organized together and 
color-coded by functional category.  
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Supplementary Figure 2. Distribution of all 20 markers across 4 time points. Each of the 20 
plots represents the distributions of a certain marker level across 4 time points. Y-axis represents natural 
log of measured marker level. Markers within the same functional category are boxed together. Border 
color of each plot corresponds to the functional category of each marker, as described in Fig. 1a.  
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Supplementary Figure 3. Quantitation of variance of three different markers during BRAFi 
treatment. Y-axis represent the variance of the marker-level distribution. Data are presented as 
mean values +/- SEM. Plots for flow cytometry experiments is the result of n = 3 biologically 
independent samples per group. For SCBC dataset, N=100 independent bootstrap runs are 
performed. Source data are provided as a Source Data file. 
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Supplementary Figure 4. SA ß-galactosidase assay of untreated control and BRAFi-treated 
cells. Left panel: Significant increased percentage of SA ß-galactosidase positive cells was 
observed in BRAFi treated day5 cells. Data are presented as mean values +/- SEM. Right panel: 
representative image of untreated melanoma cell and cells treated with BRAFi for 5 days. Scale 
bar 50um. Each experiment is the result of n = 5 biologically independent samples per group. 
Source data are provided as a Source Data file. 
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Supplementary Figure 5. Percentage of apoptosis cells across five days of BRAFi treatment. 
Data are presented as mean values +/- SD. Each experiment is the result of n = 3 biologically 
independent samples per group. Source data are provided as a Source Data file. 
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Supplementary Figure 6. Comparison of Flow cytometry analysis and SCBC data. X-axis 
represent different time points after drug treatment. Y-axis of the flow cytometry data represent 
the log of measured fluorescent intensity. Y-axis of the SCBC data represent measured level of the 
respective markers. Error bars represent 95% confidence interval of the data and the center 
represents mean value. For SCBC, N= 156, 185, 162 and 171 single cells are independently 
analyzed for day0, day1 day3 and day5 respectively. Source data are provided as a Source Data 
file. 
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Supplementary Figure 7. Visualization of SCBC data by FLOW-MAP. Each dot represents an 
individual cell. The distance between each pair of cells represents the overall multi-omic 
dissimilarity between them. Cell pairs that are close enough are linked with an edge in between. 
The colors of the dots in the central panel represent BRAFi exposure time (0, 1, 3, or 5 days) of 
the corresponding cells. Dot colors in the other panels represent the abundance of each marker in 
each cell. Markers belonging to the same functional category, as described in the bottom of the 
figure, were assigned to a certain shape and color. The dashed-line box in the panels for MITF, 
MART1, and Ki67 levels shows a small subpopulation of day-0 cells that are slow cycling with 
less melanocytic phenotype. 
9 
 
.  
 
Supplementary Figure 8. Visualization of marker abundance by t-SNE.  Each dot per plot 
represents an individual cell. The distance between each pair of dots represents the overall multi-
omic dissimilarity between that pair of cells. The dot colors in the central panel represent the drug 
exposure time of each cell. Dot colors in the other panels represent the abundance of the specified 
marker in each cell. Markers that belong to the same functional category were assigned to a certain 
shape and color, as described in the bottom of the figure. T-SNE visualizations show both the 
heterogeneity that exists at baseline as well as the progression across time through two separate 
paths. 
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Supplementary Figure 9. Visualization of marker abundance by PHATE. Each dot per plot 
represents an individual cell. The distance between each pair of dots represents the overall multi-
omic dissimilarity between that pair of cells. The dot colors in the central panel represent the drug 
exposure time of each cell. Dot colors in the other panels represent the abundance of the specified 
marker in each cell. Markers that belong to the same functional category were assigned to a certain 
shape and color, as described in the bottom of the figure. PHATE visualizations show both the 
heterogeneity that exists at baseline as well as the progression across time through two separate 
paths. 
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Supplementary Figure 10. Two modules from surprisal analysis recapitulates the 
experimental data.  Each plot represents an individual marker. Each dot within a single plot 
represents a single cell. The x-axis value of each dot represents the experimentally measured 
marker expression within a cell. The y-axis value of each dot represents the predicted marker level 
of the same cell as calculated by surprisal analysis of only module1 and module2. The strong 
positive correlation between the x- and y-axis values indicate that surprisal analysis of the two 
modules recapitulates experimentally measured marker levels per cell. Linear regression with 
Pearson correlation r and two-tailed P value, n = 674. No adjustments were made for multiple 
comparisons. 
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Supplementary Figure 11. Two modules from surprisal analysis recapitulates the 
experimental data.  a. Schematic illustration of workflow to project raw data and surprisal 
analysis-predicted data onto the same 2-dimensional space. Each cell has measured levels of all 
20 markers. Similarly, each cell also has predicted levels of all 20 markers as calculated from 
surprisal analysis. The raw and surprisal-predicted data matrices were combined to make a bigger 
matrix with double the original number of rows, each row representing a cell from raw data or 
predicted data. Each column represents a single marker, with each matrix value representing a 
single cell’s abundance of a marker. The combined, 20-dimensional dataset was projected onto a 
single t-SNE map where cells with similar levels of all 20 markers will be in nearby coordinates.   
b. Each dot represents an individual cell. In the left panel, the x-axis represents the t-SNE x-value 
of the cell projected from raw data, while the y-axis represents the t-SNE x-value of the cell 
projected from surprisal analysis-predicted data. The right panel is similar to left panel, but instead 
compared t-SNE y-values. The linear, x = y plots indicate that single cells, as projected from raw 
data and from surprisal analysis-predicted data, are in the same location in a reduced dimension; 
therefore, the experimentally measured and surprisal analysis-predicted expression profiles of all 
20 markers are similar. 
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Supplementary Figure 12. Lambda1-associated markers displays time-dependent changes. 
a. Pearson correlation of marker level vs. module1 score (lambda1) across cells from all timepoints 
of BRAFi exposure. Correlations that are not statistically significant (i.e. p > 0.05) are not shown. 
b. Representative markers that showed strongest positive (AXL, NGFR) or negative (Ki67) 
correlation with module1 score are shown in individual cells on FLOW-MAP. 
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Supplementary Figure 13. Lambda2-associated markers displays path-specific expression 
patterns. 
a. Pearson correlation of marker level with module2 score (lambda2) across cells from all time 
points after BRAFi exposure. Correlations that are not statistically significant (i.e. p > 0.05) were 
not shown.b. Representative markers that showed strongest negative correlation with module1 
score are shown in individual cells on FLOW-MAP. 
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Supplementary Figure 14. Comparison of different surprisal analysis methods. a. Surprisal 
analysis on all raw data.  b. Surprisal analysis based on z-score normalized data. c. Surprisal 
analysis on subset of data after deleting top two most variable markers: KI67 and MART1. 
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Supplementary Figure 15. Identification of Module1- and Module2-associated biophysical 
barriers. Module1 and module2-associated barriers, as defined by the points at which a module 
score changes sign, separate the cells into roughly 4 different states, labeled from 1 to 4. States 1 
and 2 are separated from states 3 and 4 by the module1-associated barrier. States 1 and 3 are 
separated from states 2 and 4 by the module2-associated barrier. 
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Supplementary Figure 16. Correlation analysis of markers with module2. a. Pearson 
correlation of marker level and module2 score in day 0 cells from single-cell dataset. The four 
most highly-correlated markers are labeled with gray arrows. b. Scatter plots showing expression 
levels of the four most highly-correlated markers versus module2 score in day-0 cells from single-
cell dataset. 
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Supplementary Figure 17. Illustration of assays using untreated MITF-reporter cells.  a. 
Untreated cells in state 1 and state 2 showed significantly different levels of MITF and Ki67. b. 
For MITF-GFP reporter line, cells with higher GFP level and lower GFP level were sorted out 
using FACS. The sorted cells were then harvested for qPCR quantitation of MITF and Ki67 
expression. 
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Supplementary Figure 18. MITF-GFP level and morphology of cells. Representative images 
from three biological replicates are shown.  
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Supplementary Figure 19. Visualization of the trajectories of the MITF-High and MITF-
Low subpopulations. Six key markers from flow cytometry assays are analyzed via three-
dimensional visualization. Each dot represent certain subpopulation analyzed at certain time point. 
Samples were projected from the original 6-dimensional space onto a 3D (left panel) or 2D (bottom 
right panel) space as a single dot.  
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Supplementary Figure 20. Illustration of assays using BRAFi-treated MITF-reporter cells.  
a. Day-5 cells in state 3 and state 4 showed different levels of MITF, MART1, PFK and Slug. b. 
For MITF-GFP reporter line, cells with higher GFP level and lower GFP level were sorted out 
using FACS. The sorted cells were then treated with BRAFi for another five days, then harvested 
for qPCR quantitation of MITF, MART1, PFK and Slug expression. 
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Supplementary Figure 21. MITF KD cells shows similar phenotype as state 2 cells.  a. 
Expression level of Ki67 from qPCR of MITF knockdown cells versus control cells. Each 
experiment is the result of n = 3 biologically independent samples per group.  b. Measured doubling time 
of MITF-knockdown cells versus control cells. Each experiment is the result of n = 4 biologically 
independent samples per group. c. Expression level of MITF, MART1, PFK and Slug after 5 days 
of BRAFi treatment in control cells and MITF-knockdown cells.  Each experiment is the result of n 
= 3 biologically independent samples per group. Data are presented as mean values +/- SEM. Source 
data are provided as a Source Data file. 
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Supplementary Figure 22. Illustration of cell state transition and network analysis. a. Cells 
transit from state1 to state2, passing over a barrier, the peak of which is the critical (tipping) point. 
The barrier is not directly measured. Instead, the tipping point is identified based on quantitative 
characteristics extracted from the single cell assays, such as increased marker-marker correlations, 
that are generally characteristic of critical points.  b. Network analysis of tipping point marker 
correlations to identify network hubs, is a strategy to identify effective drug targets for preventing 
the transition. 
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Supplementary Figure 23. Critical point transition analysis of each trajectory.  a. Critical 
point transition analysis for upper path. Critical point index Ic is calculated within each 
subpopulation associated with the upper path and color-coded onto the FLOW-MAP. Red indicates 
higher Ic value. Blue represents lower Ic value. Cluster 7, circled and labeled, shows the highest 
Ic value in the upper path.  b. Critical point transition analysis for lower path. Critical point index 
Ic is calculated within each subpopulation associated with the lower path and color-coded onto the 
FLOW-MAP. Red indicates higher Ic value. Blue represents lower Ic value. Cluster 9, circled and 
labeled, shows the highest Ic value in the lower path.  
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Supplementary Figure 24. Network structure and SNAI/Ic values for subpopulations in the 
upper path.  a. Network of subpopulations associated with the upper path. Each network structure 
plot is bordered by the color label of the corresponding cluster.  b. SNAI and Ic values of networks 
associated with subpopulations in the upper path. 
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Supplementary Figure 25. Network structure and SNAI/Ic values for subpopulations in the 
lower path.  a. Network of subpopulations associated with the lower path. Each network structure 
plot is bordered by the color label of the corresponding cluster.  b. SNAI and Ic values of networks 
associated with subpopulations in the lower path. 
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Supplementary Figure 26. Hub-score of cluster7 (C7) and cluster9 (C9).  Colors in C7 and C9 
columns indicate the hub-score value of each node found within the cluster 7 or cluster 9 networks, 
respectively. Nodes labeled with stars were further tested using drug perturbation. 
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Supplementary Figure 27. Critical point analysis across different numbers of clusters. a. 
Critical point transition analysis for upper and lower paths with cells divided into different numbers 
of clusters. The critical point index is calculated within each subpopulation from the upper and 
lower paths respectively and color-coded onto the FLOW-MAP. Red indicates a higher value, and 
blue represents a lower value. Clusters, shown where labeled, shows the highest critical point index 
value in the upper or lower path. b. Importance score, as defined by node-degree, of each node 
within each “marker-marker correlation network”, networks were calculated from the labeled cell 
cluster. Colors indicate the node-degree value of each node within networks. Nodes labeled with 
stars were further-tested with drug perturbation. 
   
29 
 
 
 
 
Supplementary Figure 28. Short-term clonogenic assay for 397 cells.  M397 was treated with 
either DMSO control or PKM2i or NFKBi or PKM2i+NFKBi or BRAFi. No significant toxicity 
to the cells was observed for using PKM2i or NFKBi or combination of both. 
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Supplementary Figure 29. Gating strategy for FACS sorting of the MITF-High and MITF-
Low subpopulations in untreated M397 cells. 
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Supplementary Table 1. List of primers used in the study 
Primer name Sequence 
PFK-F GGCAGGAGAATGTGCTGGTCAT 
PFK-R CATAAGCGACAGGCGTCAGTTTC 
MITF-F TGCCCAGGCATGAACACAC 
MITF-R GGGAAAAATACACGCTGTGAG 
MART1-F  CACGGCCACTCTTACACCAC 
MART1-R GGAGCATTGGGAACCACAGG 
Slug-F GAGCATTTGCAGACAGGTCA 
Slug-R ACAGCAGCCAGATTCCTCAT 
RPL19-F TCAGGTACAGGCTGTGATACA 
RPL19-R GGGCATAGGTAAGCGGAAGG 
 
 
 
 
